Background More data regarding effects of glucagon-like peptide-1 receptor agonists in
patients with type 2 diabetes (T2D) and heart failure (HF) are required. Objectives The …

Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …

Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

Aim To perform a post hoc analysis of the FIGHT trial, evaluating the effect of liraglutide (vs.
placebo) on the totality of events in patients with heart failure with reduced ejection fraction …

Importance Abnormal cardiac metabolism contributes to the pathophysiology of advanced
heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 …

Background: Liraglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analogue
used to treat type 2 diabetes mellitus. However, the cardiovascular safety and benefits of …

OBJECTIVE The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial (ClinicalTrials. gov reg. no. NCT01179048) demonstrated a …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce cardiovascular (CV) events
among patients with type 2 diabetes and high CV risk. Because consensus professional …

Importance After the occurrence of nonfatal cardiovascular events, recurrent events are
highly likely. Most cardiovascular outcomes trials analyze first events only; extending …

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk
for a broad range of adverse cardiovascular outcomes including coronary heart disease …